Time and PSA threshold model prognosticates long-term overall and disease-specific survival in prostate cancer patients as early as 3 months after external beam radiation therapy

Prostate Cancer and Prostatic Diseases

Volumn 8, Issue 4, 2005, Pages 353-358

  Cavanaugh, Sean X ^a,d   Fuller, C D ^a   Kupelian, P A ^b,c   Reddy, C ^c   Bradshaw, P ^a   Pollock, B H ^a   Fuss, M ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b M D ANDERSON CANCER CENTER ORLANDO   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d Cancer Treatment Institute   (United States)

Author keywords

Prognostic; Radiotherapy; Survival; Threshold; Time

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; COHORT ANALYSIS; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; DEATH; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RADIATION DOSE FRACTIONATION; RETROSPECTIVE STUDY; REVIEW; TIME; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 30544438143     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500831     Document Type: Review

References (26)

1. Carducci MA, DeWeese TL, Nelson JB. Prostate-specific antigen and other markers of therapeutic response. Urol Clin N Am 1999; 26: 291-302, viii.
2. Montie JE. Follow-up after radical prostatectomy or radiation therapy for prostate cancer. Urol Clin N Am 1994; 21: 673-676.
3. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997; 37: 1035-1041.
4. Small EJ, Roach III M. Prostate-specific antigen in prostate cancer: A case study in the development of a tumor marker to monitor recurrence and assess response. Semin Oncol 2002; 29: 264-273.
5. Taylor JM, Griffith KA, Sandler HM. Definitions of biochemical failure in prostate cancer following radiation therapy. Int J Radiat Oncol Biol Phys 2001; 50: 1212-1219.
6. Kattan MW, Fearn PA, Leibel S, Potters L. The definition of biochemical failure in patients treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys 2000; 48: 1469-1474.
7. Hanlon AL, Hanks GE. Scrutiny of the ASTRO consensus definition of biochemical failure in irradiated prostate cancer patients demonstrates its usefulness and robustness. American Society for Therapeutic Radiology and Oncology. Int J Radiat Oncol Biol Phys 2000; 46: 559-566.
8. Lee WR, Hanlon AL, Hanks GE. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: The relationship between nadir level and disease-free survival. J Urol 1996; 156 (Part 1): 450-453.
9. Thames H et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys 2003; 57: 929-943.
10. D'Amico AV et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003; 95: 1376-1383.
11. Cavanaugh SX et al. Early prostate-specific antigen (PSA) kinetics following prostate carcinoma radiotherapy: Prognostic value of a time-and-PSA threshold model. Cancer 2004; 101: 96-105.
12. Dawson NA. Response criteria in prostatic carcinoma. Semin Oncol 1999; 26: 174-184.
13. D'Amico AV et al. Determinants of prostate cancer specific survival following radiation therapy during the prostate specific antigen era. J Urol 2003;170 (Part 2): S42-S46; discussion S46-S47.
14. Sandler HM, DeSilvio ML. Surrogate end points for prostate cancer: What is prostate-specific antigen telling us? J Natl Cancer Inst 2003; 95: 1352-1353.
15. Sartor O. Endpoints in prostate cancer clinical trials. Urology 2002; 60 (Suppl 1): 101-107; discussion 107-108.
16. Pollack A et al. Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: Analysis of a prostate cancer randomized radiation dose escalation trial. Int J Radiat Oncol Biol Phys 2002; 54: 677-685.
17. D'Amico AV et al. Utilizing predictions of early prostate-specific antigen failure to optimize patient selection for adjuvant systemic therapy trials. J Clin Oncol 2000; 18: 3240-3246.
18. Swindle PW, Kattan MW, Scardino PT. Markers and meaning of primary treatment failure. Urol Clin N Am 2003; 30: 377-401.
19. Kavadi VS, Zagars GK, Pollack A. Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: Prognostic implications. Int J Radiat Oncol Biol Phys 1994; 30: 279-287.
20. Critz FA et al. Prostate-specific antigen nadir of 0.5 ng/ml or less defines disease freedom for surgically staged men irradiated for prostate cancer. Urology 1997; 49: 668-672.
21. Bagshaw MA, Ray GR, Cox RS. Radiotherapy of prostatic carcinoma: Long- or short-term efficacy (Stanford University experience). Urology 1985; 25 (Suppl): 17-23.
22. Prentice RL. Surrogate endpoints in clinical trials: Definition and operational criteria. Stat Med 1989; 8: 431-440.
23. Buyse M, Molenberghs G. Criteria for the validation of surrogate endpoints in randomized experiments. Biometrics 1998; 54: 1014-1029.
24. Molenberghs G et al. Statistical challenges in the evaluation of surrogate endpoints in randomized trials. Control Clin Trials 2002; 23: 607-625.
25. Molenberghs G, Burzykowski T, Alonso A, Buyse M. A perspective on surrogate endpoints in controlled clinical trials. Stat Methods Med Res 2004; 13: 177-206.
26. Verbel DA, Heller G, Kelly WK, Scher HI. Quantifying the amount of variation in survival explained by prostate-specific antigen. Clin Cancer Res 2002; 8: 2576-2579.